Skip to main
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 17%

Bulls say

DBV Technologies is a clinical-stage specialty biopharmaceutical company with a promising technology platform and lead product candidate, Viaskin Peanut, targeting pediatric peanut allergies. The company's cash position is expected to fund operations until at least 2Q27, providing significant runway for its upcoming regulatory submissions and potential launch. While there are clinical and financial risks involved, the company has clear potential for success in a large market, making it an attractive investment opportunity.

Bears say

DBV Technologies is facing potential delays in BLA submissions for both children and toddlers which could impact future revenue. In addition, adverse findings in the COMFORT-Toddler study, along with other potential R&D, regulatory, or commercial setbacks and new competitors in the immunotherapy space, could also hinder the company's growth and profitability. These factors contribute to a negative outlook on DBV Technologies stock as investors may have concerns about the company's ability to successfully bring its products to market and compete in a rapidly growing and competitive industry.

DBVT has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 17% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 6 analysts, DBVT has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.